Want to see BSEM full AI Analyst Report?
Top Page
BioStem Technologies
(NASDAQ:BSEM)
Select Model
Select Model
Rating:45Neutral
Price Target:
$3.00
▼(-25.19% Downside)
Action:Reiterated
Date:08/18/26
The score is held back primarily by weak and inconsistent financial performance (volatile earnings, TTM cash burn, and anomalous TTM revenue/gross profit data) and a clear downtrend in the share price versus key moving averages. The earnings call adds some support due to raised revenue guidance and strong sequential growth, but liquidity pressures, a pending contingent payment, and reliance on a 2027 manufacturing transfer keep risk elevated. Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Hospital Revenue Expansion
Hospital revenue growth supports BioStem’s shift toward institutional care, a potentially larger and more durable channel. Continued salesforce expansion and rising rep productivity could strengthen account penetration and recurring product utilization.
Negative Factors
Persistent Cash Burn
Substantial cash consumption reduces financial flexibility and raises dependence on external funding while the business scales. Continued burn could constrain commercial investment or require financing before profitability and operating cash generation improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Hospital Revenue Expansion
Hospital revenue growth supports BioStem’s shift toward institutional care, a potentially larger and more durable channel. Continued salesforce expansion and rising rep productivity could strengthen account penetration and recurring product utilization.
Read all positive factors
BioStem Technologies (BSEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$53.50M
Dividend YieldN/A
Average Volume (3M)44.17K
Price to Earnings (P/E)―
Beta (1Y)1.88
Revenue Growth-88.74%
EPS Growth-204.26%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.66
Shares Outstanding17,832,811
10 Day Avg. Volume36,608
30 Day Avg. Volume44,172
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.63
Price to Sales (P/S)1.34
P/FCF Ratio9.67
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.95
Revenue Forecast (FY)$29.00M
BioStem Technologies Business Overview & Revenue Model
Company Description
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft u...
How the Company Makes Money
BioStem Technologies primarily makes money by selling its placental-derived tissue products into clinical care settings where they are used for wound management and related surgical applications. Revenue is generated from product sales (i.e., ship...
BioStem Technologies Earnings Call Summary
Earnings Call Date:Aug 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Neutral
The call highlights strong operating execution around integration, commercial expansion, product and IP progress, sequential revenue growth (+29.5% quarter-over-quarter) and a raised revenue outlook. However, meaningful near-term financial challenges were emphasized: a $9.0 million GAAP loss, adjusted EBITDA loss, cash down to $7.0 million (≈49% decline sequentially), a $10 million contingent payment pending, and anticipated H2 margin pressure tied to legacy inventory. Management is progressing on strategic initiatives (Nasdaq uplisting, CRM/ERP integration, salesforce scale, patents, clinical data and a planned manufacturing transfer), but near-term liquidity and profitability depend on executing financing plans and the 2027 manufacturing transfer. Overall, positive operational momentum is balanced by significant near-term financial and execution risks.Positive Updates
Sequential Revenue Growth
Total revenue of $7.9 million in Q2 2026, up from $6.1 million in Q1 2026, a sequential increase of $1.8 million (+29.5%).
Negative Updates
GAAP Loss and Earnings Decline
GAAP net loss of $9.0 million, or $0.52 per share in Q2 2026, a significant deterioration versus net income of $10,000 in Q2 2025.
Read all updates
Q2-2026 Updates
Positive
Negative
Sequential Revenue Growth
Total revenue of $7.9 million in Q2 2026, up from $6.1 million in Q1 2026, a sequential increase of $1.8 million (+29.5%).
Read all positive updates
Company Guidance
BioStem raised full‑year 2026 revenue guidance to $26–$29 million (up from $25–$29M), which implies roughly $12–$15M of revenue in H2 after a H1 total of about $14M (Q1 $6.1M; Q2 $7.9M; Q2 hospital $6.7M vs Q1 $5.4M; Q2 physician office $1.1M vs $772K), and management expects the mix to be ~85–90% hospital / 10–15% physician office with continued sequential hospital growth as sales rep productivity ramps (targeting >40 W2 reps and >30 independent agents by year‑end; currently 30 reps + 5 regional directors). They forecast current gross margin at 61% with modest H2 pressure from legacy Neox/Clarix inventory but expect material margin improvement after a planned manufacturing transfer in H1 2027 (management cited potential upside of roughly 15–20 points into the 70s), operating expenses roughly flat sequentially for the rest of 2026 excluding Q3 Nasdaq uplisting costs (S&M increases to be offset by lower G&A, stock‑based comp and R&D in Q3–Q4), and noted cash of $7M at 6/30 with $5.5M operating cash use in Q2, a $10M contingent consideration being addressed, and ongoing evaluation of financing options.BioStem Technologies Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
66
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -60.31M | 47.48M | 301.83M | 16.69M | 6.88M | 4.34M |
| Gross Profit | -68.01M | 44.22M | 287.86M | 15.42M | 5.99M | 2.87M |
| EBITDA | -22.00M | -469.73K | 31.49M | -7.55M | -6.52M | -602.00K |
| Net Income | -28.29M | -6.58M | 31.88M | -8.48M | -7.07M | -1.45M |
Balance Sheet | ||||||
| Total Assets | 48.82M | 50.03M | 140.55M | 14.56M | 3.47M | 2.67M |
| Cash, Cash Equivalents and Short-Term Investments | 6.96M | 29.55M | 22.83M | 239.41K | 772.14K | 340.33K |
| Total Debt | 1.22M | 3.33M | 4.50M | 4.77M | 5.21M | 4.83M |
| Total Liabilities | 1.35K | 10.89M | 99.67M | 15.90M | 7.42M | 8.47M |
| Stockholders Equity | 27.61M | 39.14M | 40.88M | -1.34M | -4.08M | -5.96M |
Cash Flow | ||||||
| Free Cash Flow | -8.83M | 6.59M | 24.05M | -3.60M | -2.11M | -152.29K |
| Operating Cash Flow | -5.92M | 9.94M | 24.48M | -3.50M | -1.64M | -109.44K |
| Investing Cash Flow | -16.68M | -2.10M | -1.68M | -210.33K | -469.48K | -7.85K |
| Financing Cash Flow | -1.28M | -1.12M | -206.78K | 3.18M | 597.71K | 357.42K |
BioStem Technologies Technical Analysis
Negative
4.01
Price Trends
3.60
Negative
4.05
Negative
4.49
Negative
Market Momentum
-0.12
Positive
43.23
Neutral
36.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSEM, the sentiment is Negative. The current price of 4.01 is above the 20-day moving average (MA) of 3.51, above the 50-day MA of 3.60, and below the 200-day MA of 4.49, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 43.23 is Neutral, neither overbought nor oversold. The STOCH value of 36.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSEM.
BioStem Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $26.14M | -0.81 | -202.41% | ― | -42.74% | 20.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $28.02M | -0.45 | -523.04% | ― | ― | 73.74% | |
45 Neutral | $53.50M | -1.80 | -76.13% | ― | -88.74% | -204.26% | |
42 Neutral | $20.15M | -0.19 | 411.46% | ― | -51.03% | -35.20% | |
42 Neutral | $17.43M | -0.35 | 41.94% | ― | ― | ― | |
40 Underperform | $17.26M | -0.56 | 203.55% | ― | 4.35% | 20.37% |
* Healthcare Sector Average
BSEM
BioStem Technologies
3.15
-3.33
-51.39%
PLUR
Pluri
1.63
-2.88
-63.86%
CELU
Celularity
0.74
-2.87
-79.61%
JSPR
Jasper Therapeutics
0.75
-2.10
-73.68%
NCEL
NewcelX
3.39
-24.51
-87.85%
LGVN
Longeveron
0.79
-0.04
-4.84%
BioStem Technologies Corporate Events
Business Operations and StrategyDelistings and Listing Changes
BioStem Technologies Uplists to Nasdaq Capital Market
Positive
Aug 7, 2026
On August 6, 2026, BioStem Technologies announced that The Nasdaq Stock Market approved the company’s common stock for listing on the Nasdaq Capital Market, marking an uplisting from the OTCID Basic Market. Trading in BioStem’s shares ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.